- Home
- CDTG vs BCAB Comparison
CDTG vs BCAB Comparison
Compare CDTG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- BCAB
- Stock Information
- Founded
- CDTG 2012
- BCAB 2007
- Country
- CDTG China
- BCAB United States
- Employees
- CDTG N/A
- BCAB N/A
- Industry
- CDTG
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- CDTG
- BCAB Health Care
- Exchange
- CDTG NYSE
- BCAB Nasdaq
- Market Cap
- CDTG 24.5M
- BCAB 27.0M
- IPO Year
- CDTG 2024
- BCAB 2020
- Fundamental
- Price
- CDTG $0.66
- BCAB $0.43
- Analyst Decision
- CDTG
- BCAB Buy
- Analyst Count
- CDTG 0
- BCAB 2
- Target Price
- CDTG N/A
- BCAB $1.00
- AVG Volume (30 Days)
- CDTG 748.6K
- BCAB 538.7K
- Earning Date
- CDTG 07-03-2025
- BCAB 05-06-2025
- Dividend Yield
- CDTG N/A
- BCAB N/A
- EPS Growth
- CDTG N/A
- BCAB N/A
- EPS
- CDTG 0.72
- BCAB N/A
- Revenue
- CDTG $31,432,824.00
- BCAB $11,000,000.00
- Revenue This Year
- CDTG N/A
- BCAB N/A
- Revenue Next Year
- CDTG N/A
- BCAB N/A
- P/E Ratio
- CDTG $0.98
- BCAB N/A
- Revenue Growth
- CDTG N/A
- BCAB N/A
- 52 Week Low
- CDTG $0.52
- BCAB $0.24
- 52 Week High
- CDTG $4.64
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- BCAB 51.43
- Support Level
- CDTG N/A
- BCAB $0.43
- Resistance Level
- CDTG N/A
- BCAB $0.58
- Average True Range (ATR)
- CDTG 0.00
- BCAB 0.06
- MACD
- CDTG 0.00
- BCAB 0.00
- Stochastic Oscillator
- CDTG 0.00
- BCAB 45.21
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.